Stocks · Healthcare · Medical - Diagnostics & Research
Natera, Inc. NTRA
$410.35 +0.46% Close, Oct 2, 2026 · NASDAQ · Market cap $58.77B
Strong trendLow risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned +153.9%, ahead of the S&P 500 by 138.8 percentage points.
- Revenue over the last four quarters was $2.71B, up 37.8% from a year earlier.
- The stock is in an uptrend: above its 200-day average for 90 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 21%
- FCF growth (TTM, YoY)Bottom 22%
- Revenue growth, 3-year CAGRTop 16%
- Revenue growth accelerationTop 34%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 43%
- Gross marginTop 49%
- Operating marginBottom 47%
- Accruals (lower is better)Top 20%
- Interest coverBottom 22%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 31%
- Free-cash-flow yieldTop 35%
- EBITDA / enterprise valueTop 38%
- Sales / enterprise valueBottom 19%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 17%
- 6-month returnTop 9%
- 1-year return vs S&P 500Top 8%
- Distance from 52-week highTop 3%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 19%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 28%
- Upside to consensus price targetBottom 4%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 44%
- Maximum drawdown, 3 yearsTop 4%
- Beta vs S&P 500 (lower is better)Top 36%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 36.6% | 37.8% | ↑ |
| Gross margin | 62.9% | 65.3% | ↑ |
| Operating margin | -14.9% | -10.7% | ↑ |
| FCF margin | 5.3% | 2.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 37.8% | 36.6% | ↑ | Top 21% |
| Gross margin | 65.3% | 62.9% | ↑ | Top 49% |
| Operating margin | -10.7% | -14.9% | ↑ | Bottom 47% |
| Net margin | -7.1% | -12.9% | ↑ | — |
| Free-cash-flow margin | 2.6% | 5.3% | ↓ | — |
| Return on invested capital | -10.0% | — | Top 43% | |
| Revenue growth, 3-year CAGR | 41.1% | — | Top 16% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -15.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 14.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -1.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -29.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.09%
- Shareholder yield
- -0.09%
- Share count change, 1 year
- +5.1%
- Share count change, 3-year CAGR
- +8.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 7, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +26.0%
- Average 2-day reaction, last 8
- +0.3%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $350.07
- Target vs current price
- -14.7%
- Analysts with a rating
- 28
- Share rating Buy or Strong Buy
- 89%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +4.8% | -3.4% | +15.1% | +18.4% | — |
| May 7, 2026 | -3.3% | +2.2% | -9.2% | +3.3% | +25.7% |
| Feb 26, 2026 | +168.4% | +2.0% | -4.2% | -6.8% | -3.8% |
| Nov 6, 2025 | -65.9% | -0.7% | +4.8% | +21.1% | +13.9% |
| Aug 7, 2025 | -20.2% | +2.1% | +14.2% | +20.6% | +39.9% |
| May 8, 2025 | +21.9% | +1.5% | -5.5% | +3.4% | -14.7% |
| Feb 27, 2025 | -7.6% | -2.5% | -7.9% | -6.7% | -5.0% |
| Nov 12, 2024 | +54.4% | +0.9% | +14.5% | +24.2% | +28.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.47 | -$0.49 | +4.8% | $752.8M |
| May 7, 2026 | -$0.56 | -$0.54 | -3.3% | $696.6M |
| Feb 26, 2026 | $0.35 | -$0.51 | +168.4% | $665.5M |
| Nov 6, 2025 | -$0.64 | -$0.39 | -65.9% | $592.2M |
| Aug 7, 2025 | -$0.74 | -$0.62 | -20.2% | $546.6M |
| May 8, 2025 | -$0.50 | -$0.64 | +21.9% | $501.8M |
| Feb 27, 2025 | -$0.41 | -$0.38 | -7.6% | $476.1M |
| Nov 12, 2024 | -$0.26 | -$0.57 | +54.4% | $439.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 21.39× | — | — | Bottom 19% |
| Free-cash-flow yield | 0.12% | — | — | Top 35% |
| Earnings yield | -0.33% | — | — | Top 31% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 90
- Days above the 200-day average
- 90
- 50-day average slope (20 days)
- +13.8%
- 200-day average slope (20 days)
- +6.0%
- Distance from 50-day average
- +23.9%
- Distance from 200-day average
- +64.8%
- RSI (14)
- 78.2
- Relative volume
- 1.35×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 52.2%
- Volatility vs own 5-year history
- 52th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.89
- Correlation with S&P 500
- 0.30
- Current drawdown from 1-year high
- -1.0%
- Maximum drawdown, 3 years
- -28.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 17, 2021 | May 11, 2022 | -77.7% | 163 days | 588 days (Sep 13, 2024) |
| Feb 12, 2021 | May 21, 2021 | -30.8% | 68 days | 82 days (Sep 17, 2021) |
| Jan 7, 2026 | Mar 27, 2026 | -28.2% | 55 days | 60 days (Jun 24, 2026) |
| Feb 5, 2025 | Apr 8, 2025 | -25.3% | 43 days | 112 days (Sep 18, 2025) |
| Jan 19, 2021 | Jan 27, 2021 | -19.1% | 6 days | 12 days (Feb 12, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $58.77B
- EPS, diluted (TTM)
- -$1.36
- Revenue (TTM)
- $2.71B
- 52-week range
- $157.43 – $427.47
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $625.5M | $820.2M | $1.08B | $1.70B | $2.31B |
| Gross profit | $307.1M | $364.0M | $492.7M | $1.02B | $1.50B |
| Operating income | -$468.2M | -$541.0M | -$446.2M | -$222.3M | -$309.9M |
| Net income | -$471.7M | -$547.8M | -$434.8M | -$190.4M | -$208.2M |
| EPS (diluted) | -$5.21 | -$5.57 | -$3.78 | -$1.53 | -$1.52 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $439.8M | $476.1M | $501.8M | $546.6M | $592.2M | $665.5M | $696.6M | $752.8M |
| Net income | -$31.6M | -$53.8M | -$66.9M | -$100.9M | -$87.5M | $47.3M | -$85.1M | -$67.0M |
| EPS (diluted) | -$0.26 | -$0.41 | -$0.50 | -$0.74 | -$0.64 | $0.35 | -$0.60 | -$0.47 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$335.2M | -$431.5M | -$247.0M | $135.7M | $215.3M |
| Capital expenditure | -$41.0M | -$47.7M | -$39.2M | -$66.4M | -$106.2M |
| Free cash flow | -$376.3M | -$479.2M | -$286.2M | $69.2M | $109.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $576.2M | $452.6M | $254.5M | $30.3M | $47.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.09B
- Total assets
- $2.66B
- Total liabilities
- $836.0M
- Total debt
- $238.5M
- Net debt
- -$853.0M
- Shareholders’ equity
- $1.82B
As of Jun 30, 2026 (filed Aug 7, 2026).
Short interest
- Shares sold short
- 4,797,175
- Days to cover
- 4.70
- Change vs previous report
- -13.0%
FINRA short interest, settlement date Sep 15, 2026.